InterCure Ltd.
NASDAQ:INCR · NASDAQ Global Market
-$0.04 today
Vol 0.01M · Avg 0.04M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$36.8M +49.5% | -$72.8M -14.6% | -$63.5M -245.2% | $43.7M +499.7% | $7.3M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $17.1M +11.6% | $15.4M +16.7% | $13.2M +12.5% | $11.7M +58.2% | $7.4M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$7.3M +49.6% | -$14.5M -746.4% | $2.2M +2317.2% | $93.0K -99.2% | $11.4M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $2.4M +6.5% | $2.3M -12.0% | $2.6M -70.9% | $8.9M +38.1% | $6.5M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $18.9M +305.4% | -$9.2M +78.9% | -$43.5M -1342.9% | -$3.0M -82.5% | -$1.7M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $9.3M -29.9% | $13.3M +156.5% | -$23.5M -28.5% | -$18.3M -317.9% | $8.4M | $592.6M | $1.3B | $626.2M |
| Inventory | $15.9M +191.4% | -$17.4M -143.4% | $40.2M +152.9% | -$76.0M -324.8% | -$17.9M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$8.8M +0.9% | -$8.9M +81.3% | -$47.6M -183.5% | $57.0M +1946.4% | $2.8M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $2.5M -36.7% | $3.9M +130.7% | -$12.6M -136.9% | $34.2M +576.7% | $5.1M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $22.5M +88.4% | $11.9M -66.3% | $35.4M +448.7% | -$10.2M -72.1% | -$5.9M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $16.8M +125.2% | -$66.9M -24.8% | -$53.6M -204.6% | $51.3M +104.9% | $25.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$3.5M +18.9% | -$4.4M -67.1% | -$2.6M +86.7% | -$19.7M -40.7% | -$14.0M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $1.7M +311.1% | $405.0K +109.6% | -$4.2M +49.5% | -$8.3M +56.4% | -$19.1M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 +100.0% | -$1.2M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$107.0K -100.5% | $21.7M +86.9% | $11.6M +110.1% | -$114.4M -271.1% | -$30.8M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$2.0M -111.3% | $17.7M +270.6% | $4.8M +103.3% | -$142.5M -118.5% | -$65.2M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$29.1M -476.2% | $7.7M +112.5% | -$62.0M -145.0% | $137.7M +109.2% | $65.8M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $1.5M -95.6% | $34.0M | $0 | $0 -100.0% | $128.7M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$19.0M -24.5% | -$15.3M +26.9% | -$20.9M -21.0% | -$17.3M -611.1% | $3.4M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$46.7M -276.4% | $26.5M +131.9% | -$82.9M -168.8% | $120.4M -39.2% | $197.9M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | -$44.0K -12.8% | -$39.0K -113.1% | $297.0K -95.8% | $7.2M +257.8% | -$4.5M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$31.9M -39.6% | -$22.8M +82.6% | -$131.4M -461.4% | $36.4M -77.0% | $158.3M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $13.3M +118.6% | -$71.3M -26.8% | -$56.3M -278.4% | $31.5M +186.8% | $11.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Edap Tms S.a.
EDAP
$178.23M
Assertio Holdings, Inc.
NASDAQ:ASRT
$151.86M
American Well Corporation
NYSE:AMWL
$146.70M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$145.60M
Cardiol Therapeutics Inc.
NASDAQ:CRDL
$122.76M
Repare Therapeutics Inc.
RPTX
$114.24M
Fortress Biotech, Inc.
NASDAQ:FBIO
$100.49M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$87.51M
MindWalk Holdings Corp.
NASDAQ:HYFT
$70.30M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.47M
SEC Filings
Recent regulatory filings
No filings found.
Does INCR generate free cash flow?
InterCure Ltd. (INCR) generated $13.29M of free cash flow in fiscal 2025.
How much operating cash flow does INCR produce?
Operating cash flow was $16.84M, before capital expenditures of $3.55M.
Explore More
Continue the stock analysis
Jump to another research area for this company.